Description:
Cyt387 is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50 = 11 nM and 18 nM respectively). It has been shown to decrease cancer stem cell associated tumor burden in a mouse model of human ovarian cancer. It is commonly used as a therapy for myelofibrosis.
- Molecular Weight: 414.46
- Molecular Formula: C23H22N6O2
Purity: >98%
Canonical SMILES:
C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N
InChI:
InChI=1S/C23H22N6O2/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28)
InChIKey: ZVHNDZWQTBEVRY-UHFFFAOYSA-N
- Melting Point: 232-234°C
- Solubility: Soluble in DMSO
- Appearance: Solid Powder
- Application: An orally bioavailable small-molecule inhibitor of Janus kinases 1 and 2 (JAK1/2) with potential antineoplastic activity (IC50s = 11 and 18 nM, respectively)
- Storage: Store at -20 °C
Synonyms:
Momelotinib; N-(Cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide; CYT 11387; CYT 387; CYT-387; CYT387; CYT-0387; GS 0387
More details are to be found on supplier website
